The 55% rate of BRCA1/2 mutations in the Study 19 tumor-sequenced subpopulation was higher than the 20-26% rate seen in other HG-SOC tumor-sequencing studies (Supplemental Table 2). This evidence concerns the gene BRCA1 and neoplasm.